Downregulation of the expression of galanin impairs erectile function in hypoandrogenic rats.
eNOS
erectile dysfunction
galanin
testosterone
Journal
Sexual medicine
ISSN: 2050-1161
Titre abrégé: Sex Med
Pays: England
ID NLM: 101631053
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
07
02
2023
revised:
05
04
2023
accepted:
23
05
2023
medline:
23
6
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
epublish
Résumé
The relationship between galanin and erectile function under low androgen levels is still unclear. To explore whether a low testosterone level damages the erection of a rat by regulating the expression of galanin and GalR in penile cavernous tissue. Thirty-six male Sprague-Dawley rats, 8 weeks of age, were randomly grouped as follows (n = 6): control, castration, castration + testosterone replacement, control + transfection, castration + transfection, and castration + empty transfection. At 4 weeks after castration, rats in the transfection group were injected with lentivirus carrying the targeting galanin gene (2 × 10 ICPmax/MAP and the expression of galanin in the corpus cavernosum in castrated rats were obviously decreased as compared with those in the control rats. The castrated rats showed remarkably lower ICPmax/MAP, galanin, GalR1-3, p-eNOS/eNOS, and NO content and markedly higher ROCK1 and ROCK2 in penile tissues than the control group ( Upregulating the expression of galanin in the penile corpus cavernosum might be a novel method of treating erectile dysfunction caused by a low androgen level. The conclusions obtained in the animal experiments need to be confirmed in human data. The erectile function of hypoandrogen rats might be inhibited by downregulating the level of galanin and GalR1-3, upregulating ROCK1 and ROCK2 levels, and inhibiting the eNOS/NO signaling pathway in penile corpus cavernosum.
Sections du résumé
Background
UNASSIGNED
The relationship between galanin and erectile function under low androgen levels is still unclear.
Aim
UNASSIGNED
To explore whether a low testosterone level damages the erection of a rat by regulating the expression of galanin and GalR in penile cavernous tissue.
Methods
UNASSIGNED
Thirty-six male Sprague-Dawley rats, 8 weeks of age, were randomly grouped as follows (n = 6): control, castration, castration + testosterone replacement, control + transfection, castration + transfection, and castration + empty transfection. At 4 weeks after castration, rats in the transfection group were injected with lentivirus carrying the targeting galanin gene (2 × 10
Outcomes
UNASSIGNED
ICPmax/MAP and the expression of galanin in the corpus cavernosum in castrated rats were obviously decreased as compared with those in the control rats.
Results
UNASSIGNED
The castrated rats showed remarkably lower ICPmax/MAP, galanin, GalR1-3, p-eNOS/eNOS, and NO content and markedly higher ROCK1 and ROCK2 in penile tissues than the control group (
Clinical Translation
UNASSIGNED
Upregulating the expression of galanin in the penile corpus cavernosum might be a novel method of treating erectile dysfunction caused by a low androgen level.
Strengths and Limitations
UNASSIGNED
The conclusions obtained in the animal experiments need to be confirmed in human data.
Conclusion
UNASSIGNED
The erectile function of hypoandrogen rats might be inhibited by downregulating the level of galanin and GalR1-3, upregulating ROCK1 and ROCK2 levels, and inhibiting the eNOS/NO signaling pathway in penile corpus cavernosum.
Identifiants
pubmed: 37351545
doi: 10.1093/sexmed/qfad029
pii: qfad029
pmc: PMC10281959
doi:
Types de publication
Journal Article
Langues
eng
Pagination
qfad029Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society of Sexual Medicine.
Références
Life Sci. 1987 Dec 28;41(26):2783-90
pubmed: 2447463
Front Endocrinol (Lausanne). 2017 Jul 03;8:143
pubmed: 28729853
Neuroscience. 2008 Nov 11;157(1):174-87
pubmed: 18824073
Andrology. 2021 Jul;9(4):1264-1274
pubmed: 33657666
Prim Care. 2019 Jun;46(2):249-255
pubmed: 31030826
Biochemistry. 1998 May 12;37(19):6711-7
pubmed: 9578554
J Androl. 2008 Jan-Feb;29(1):70-84
pubmed: 17699803
J Sex Med. 2015 Jul;12(7):1522-32
pubmed: 25923835
Pharmacol Rev. 2015;67(1):118-75
pubmed: 25428932
J Sex Med. 2010 Feb;7(2 Pt 1):758-68
pubmed: 19912487
Neuroscience. 1998 Aug;85(3):819-26
pubmed: 9639275
BJU Int. 2005 Apr;95(6):890-4
pubmed: 15794804
Gastroenterology. 1989 Aug;97(2):260-4
pubmed: 2472997
Sex Med Rev. 2018 Oct;6(4):572-582
pubmed: 29631978
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2717-22
pubmed: 18272487
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):680-688
pubmed: 29280463
Br J Pharmacol. 1998 Aug;124(8):1623-32
pubmed: 9756377
Andrologia. 2020 Aug;52(7):e13627
pubmed: 32352595
FEBS Lett. 1983 Nov 28;164(1):124-8
pubmed: 6197320
Life Sci. 1986 Jul 14;39(2):103-10
pubmed: 2425211
J Sex Med. 2010 Dec;7(12):3857-67
pubmed: 20807329
J Biol Chem. 1998 Sep 4;273(36):23321-6
pubmed: 9722565
J Sex Med. 2005 May;2(3):341-6
pubmed: 16422865
J Neurochem. 2007 Feb;100(3):790-801
pubmed: 17263797
Circ Res. 2005 May 27;96(10):1072-8
pubmed: 15879307
Endocrine. 2011 Dec;40(3):400-7
pubmed: 21894515
Amino Acids. 2006 Oct;31(3):231-9
pubmed: 16733616
J Neurosci Res. 2009 Apr;87(5):1107-14
pubmed: 19006083
Sex Med Rev. 2019 Oct;7(4):661-668
pubmed: 30987932
Andrology. 2020 Mar;8(2):497-508
pubmed: 31610097
Endocrinology. 2000 May;141(5):1780-94
pubmed: 10803589
J Sex Med. 2016 Feb;13(2):135-43
pubmed: 26953828
Sex Med. 2021 Aug;9(4):100348
pubmed: 34186306
Andrologia. 2022 Oct;54(9):e14503
pubmed: 35778809
J Sex Med. 2017 Mar;14(3):323-335
pubmed: 28162947
Andrology. 2022 Jul;10(5):997-1007
pubmed: 35466583
Andrology. 2020 Nov;8(6):1875-1883
pubmed: 32594586
Int J Impot Res. 2018 Jun;30(3):122-128
pubmed: 29725076
Eur J Pharmacol. 1989 May 30;164(3):583-6
pubmed: 2475349
Urology. 2019 Nov;133:249.e1-249.e7
pubmed: 31476348
Eur J Pharmacol. 1991 Jan 25;193(1):75-80
pubmed: 1710989
Andrologia. 2022 Sep;54(8):e14477
pubmed: 35596534
Biochem Biophys Res Commun. 2014 Mar 28;446(1):316-21
pubmed: 24602615
Cardiovasc Hematol Agents Med Chem. 2009 Oct;7(4):322-30
pubmed: 19607644
Medicina (Kaunas). 2021 Oct 14;57(10):
pubmed: 34684140
J Neurochem. 2013 Oct;127(2):199-208
pubmed: 23895321
Pflugers Arch. 2012 Aug;464(2):205-15
pubmed: 22729753
Br J Pharmacol. 2015 Mar;172(5):1277-91
pubmed: 25363469